EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastasesCombination therapies show promise for lung cancer with brain spread

This systematic review and network meta-analysis evaluated treatment strategies for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who present with brain metastases. The analysis included a total of 5432 patients to compare various combination strategies against EGFR-TKI monotherapy. The combination strategies investigated included the addition of chemotherapy, anti-angiogenic therapy, radiotherapy, or bispecific antibody therapy to the standard of care for EGFR-mutated NSCLC.

The primary outcome measured was overall survival (OS). The analysis revealed that the combination of EGFR-TKI plus anti-angiogenic therapy yielded the most favorable estimate for OS compared to monotherapy, with a reported hazard ratio (HR) of 0.63 (95% CI, 0.49-0.80). While this indicates a favorable association, the authors note that the OS rankings were less definitive than other metrics.

Secondary outcomes included progression-free survival (PFS) and intracranial progression-free survival (iPFS). For both PFS and iPFS, the combination of EGFR-TKI plus chemotherapy was identified as the most favorable estimate. The reported hazard ratio for PFS was 0.52 (95% CI, 0.44-0.61). The reported hazard ratio for iPFS was 0.36 (95% CI, 0.25-0.52). These results suggest that adding chemotherapy to an EGFR-TKI regimen may provide a more robust signal for controlling disease progression, particularly within the central nervous system.

Safety and tolerability data were reported descriptively for Grade \u2265 3 treatment-related adverse events (TRAEs). Specific rates for serious adverse events or treatment discontinuations were not reported in the data. Because of the descriptive nature of the safety reporting, a detailed quantitative comparison of tolerability between the different combination regimens was not possible in this analysis.

Several methodological limitations were identified in the study. The authors noted that OS rankings were less definitive than other outcomes. Furthermore, randomized evidence for intracranial progression-free survival (iPFS) remained sparse. Results regarding radiotherapy-based combinations were considered exploratory, and the findings for both radiotherapy- and bispecific antibody-based combinations should be interpreted with caution due to the limited data available.

Clinically, these results suggest that while both anti-angiogenic and chemotherapy additions to EGFR-TKI therapy show potential benefits, the choice of combination should be individualized. Clinicians must weigh the treatment goals, the specific generation of the EGFR-TKI used, the extent of intracranial disease burden, and the expected toxicity profile for each patient. The potential OS benefit of adding anti-angiogenic therapy remains an association that requires careful interpretation. Questions remain regarding the long-term durability of response in patients receiving bispecific antibodies or radiotherapy-based combinations, as these areas currently lack robust evidence.